Because TNBC patients are HER2 negative and not suitable for Trastuzumab or other therapies targeting HER2, novel tumor cell–specific markers such as vascular endothelial growth factor (VEGF) A, cathepsin D (cath-D) and CD40 are identified and mAb-based targeted therapy appro?A3B2 ?>aches are undergoing for TNBC treatment. This evidence concerns the gene ERBB2 and neoplasm.